Hikma Pharmaceuticals (LON:HIK) Shares Cross Above Two Hundred Day Moving Average – Here’s Why

Hikma Pharmaceuticals PLC (LON:HIK)’s share price crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of GBX 1,921.36 ($24.10) and traded as high as GBX 2,000 ($25.08). Hikma Pharmaceuticals shares last traded at GBX 1,991.27 ($24.98), with a volume of 387,164 shares traded.

Analyst Ratings Changes

Separately, Berenberg Bank upgraded Hikma Pharmaceuticals to a “buy” rating and lifted their target price for the company from GBX 2,100 ($26.34) to GBX 2,400 ($30.10) in a report on Monday, September 2nd.

Hikma Pharmaceuticals Stock Up 0.2 %

The company has a debt-to-equity ratio of 55.48, a current ratio of 1.66 and a quick ratio of 1.27. The company has a market cap of £4.42 billion, a PE ratio of 3,063.48, a P/E/G ratio of 2.38 and a beta of 0.41. The business’s 50 day moving average is GBX 1,914.85 and its 200-day moving average is GBX 1,921.59.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.